[en] OBJECTIVES: Infliximab is the first anti-TNFalpha accepted by the Food and Drug Administration for use in inflammatory bowel disease treatment. Few clinical, biological and genetic factors tend to predict response in Crohn's disease (CD) patient subcategories, none widely predicting response to infliximab. DESIGN AND METHODS: Twenty CD patients showing clinical response or non response to infliximab were used for serum proteomic profiling on Surface Enhanced Lazer Desorption Ionisation-Time of Flight-Mass Spectrometry (SELDI-TOF-MS), each before and after treatment. Univariate and multivariate data analysis were performed for prediction and characterization of response to infliximab. RESULTS: We obtained a model of classification predicting response to treatment and selected relevant potential biomarkers, among which platelet aggregation factor 4 (PF4). We quantified PF4, sCD40L and IL-6 by ELISA for correlation studies. CONCLUSIONS: This first proteomic pilot study on response to infliximab in CD suggests association between platelet metabolism and response to infliximab and requires validation studies on a larger cohort of patients.
Rutgeerts P., Van Assche G., and Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126 (2004) 1593-1610
Rutgeerts P., Van Assche G., and Vermeire S. Review article: infliximab therapy for inflammatory bowel disease-seven years on. Aliment Pharmacol Ther 23 (2006) 451-463
Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005) 2462-2476
Kupcova V., Turecky L., Detkova Z., Prikazska M., and Keleova A. Changes in acute phase proteins after anti-tumor necrosis factor antibody (infliximab) treatment in patients with Crohn's disease. Physiol Res 52 (2003) 89-93
Dideberg V., Theatre E., Farnir F., et al. The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease. Pharmacogenet Genomics 16 (2006) 727-734
Gustot T., Lemmers A., Louis E., et al. Profile of soluble cytokine receptors in Crohn's disease. Gut 54 (2005) 488-495
Mascheretti S., and Schreiber S. The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn's disease. Pharmacogenomics 5 (2004) 479-486
Hlavaty T., Pierik M., Henckaerts L., et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther 22 (2005) 613-626
Louis E.J., Watier H.E., Schreiber S., et al. Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. Pharmacogenet Genomics 16 (2006) 911-914
Mitoma H., Horiuchi T., Hatta N., et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 128 (2005) 376-392
Petricoin E.F., Ornstein D.K., and Liotta L.A. Clinical proteomics: applications for prostate cancer biomarker discovery and detection. Urol Oncol 22 (2004) 322-328
Coombes K.R., Morris J.S., Hu J., Edmonson S.R., and Baggerly K.A. Serum proteomics profiling-a young technology begins to mature. Nat Biotechnol 23 (2005) 291-292
de Seny D., Fillet M., Meuwis M.A., et al. Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach. Arthritis Rheum 52 (2005) 3801-3812
Meuwis M.A., Fillet M., Geurts P., et al. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Pharmacol 73 (2007) 1422-1433
Geurts P., Fillet M., de Seny D., et al. Proteomic mass spectra classification using decision tree based ensemble methods. Bioinformatics 21 (2005) 3138-3145
Lam Y.W., Mobley J.A., Evans J.E., Carmody J.F., and Ho S.M. Mass profiling-directed isolation and identification of a stage-specific serologic protein biomarker of advanced prostate cancer. Proteomics 5 (2005) 2927-2938
Gao Q., Meijer M.J., Schluter U.G., et al. Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease. Inflamm Bowel Dis 13 (2007) 693-702
Simi M., Leardi S., Tebano M.T., Castelli M., Costantini F.M., and Speranza V. Raised plasma concentrations of platelet factor 4 (PF4) in Crohn's disease. Gut 28 (1987) 336-338
Slungaard A. Platelet factor 4: a chemokine enigma. Int J Biochem Cell Biol 37 (2005) 1162-1167
Bikfalvi A. Platelet factor 4: an inhibitor of angiogenesis. Semin Thromb Hemost 30 (2004) 379-385
Danese S., Motte Cd Cde L., and Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol 99 (2004) 938-945
Louis E., Vermeire S., Rutgeerts P., et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 37 (2002) 818-824
Danese S., de la Motte C., Sturm A., et al. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology 124 (2003) 1249-1264
Danese S., Sans M., Scaldaferri F., et al. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol 176 (2006) 2617-2624